Eli Lilly Bets Big on Weight-Loss Pill With $550 Million Inventory Stockpile

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial statements, a filing showed on Wednesday.